From: Toward population specific and personalized treatment of Helicobacter pylori infection
WHO region | Prevalence of primary resistance | ||
---|---|---|---|
Clarithromycin | Metronidazole | Levofloxacin | |
Americas region [23] | |||
 2006–2008 | 11 (3–19) | 26 (10–42) | N/A |
 2009–2011 | 9 (2–15) | 21 (13–33) | 11 (5–16) |
 2012–2016 | 20 (12–28) | 29 (0–59) | 19 (5–16) |
European region [23] | |||
 2006–2008 | 28 (24–32) | 38 (33–43) | 15 (12–18) |
 2009–2011 | 23 (20–27) | 33 (25–40) | 13 (9–17) |
 2012–2016 | 28 (25–31) | 46 (34–58) | 12 (8–15) |
Asia-Pacific region [5] | |||
 2006–2010 | 19 (16–23) | 50 (44–56) | 17 (13–21) |
 2011–2015 | 21 (18–25) | 45 (39–48) | 27 (21–34) |